Kyle Lefkoff

Kyle Lefkoff is the Founder and General Partner of Boulder Ventures Ltd., an early-stage venture firm he has run for roughly three decades. Over a career spanning nearly forty years as a venture capitalist, he has backed approximately 65 Colorado companies across both the information technology and biotechnology sectors. Boulder Ventures has deployed roughly $500 million across eight funds; the firm closed its eighth fund at $58 million in November 2022 and, as of January 2026, was raising a ninth fund targeting around $60 million.

Lefkoff's signature accomplishment is Array BioPharma, which he co-founded in May 1998 with chemist Marv Caruthers and a group of former Amgen scientists. He served as Chairman of the Board from the company's inception through August 2018, when Array's targeted melanoma therapy received FDA approval. In July 2019, Pfizer acquired Array for $11.8 billion in cash — the largest acquisition of a venture-backed life sciences company in Colorado history.

He was educated at Vassar College, earning a B.A. in Economics summa cum laude in 1981, and completed a Fellowship in Economic History at the London School of Economics in 1980. He went on to earn an MBA in Finance from the University of Chicago in 1985.

Beyond venture capital, Lefkoff is an experienced alpinist and mountain guide. He was the founding Chairman of the Board of the American Institute for Avalanche Research and Education (AIARE), which sets the avalanche-education standard for mountain guides and snow professionals in the United States.

• Invests in early-stage Information Technology and Biotechnology companies, leaning toward enterprise software, developer tools, and life sciences.
• Primarily a Series A investor with selective seed-stage participation; also follows on through Series B. Check sizes typically run ~$1M–$5M.
• Strong geographic conviction: the firm explicitly concentrates on the Colorado Front Range and the Mid-Atlantic, leveraging "decades-long relationships with entrepreneurs and investors" in those regions.
• Comfortable with deep-science and technically complex businesses — Lefkoff's track record of company-building (founding and chairing Array BioPharma) signals a hands-on, long-horizon partner rather than a passive check-writer.
• Pattern of backing companies that reach durable outcomes — IPOs and acquisitions by strategics like Pfizer, Gilead, Cisco, HP, and EMC.